SABSW
SAB Biotherapeutics, Inc. [SABSW] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
SABSW Stock Summary
In the News
SABSW Financial details
Company Rating
Neutral
Market Cap
41.42M
Income
-42.24M
Revenue
2.24M
Book val./share
9.67
Cash/share
9.54
Dividend
-
Dividend %
-
Employees
57
Optionable
No
Shortable
Yes
Earnings
31 Mar 2023
P/E
-11.42
Forward P/E
-
PEG
-1.47
P/S
0.3
P/B
20.4
P/C
0
P/FCF
0.87
Quick Ratio
0.26
Current Ratio
0.34
Debt / Equity
0.1
LT Debt / Equity
0.07
-
-
EPS (TTM)
-7.66
EPS next Y
-
EPS next Q
-
EPS this Y
77.26%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
103.3%
Revenue last 5Y
-8.24%
Revenue Q/Q
-75.93%
EPS Q/Q
297.94%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
2.61%
Inst Trans
1.55%
ROA
-96%
ROE
-121%
ROC
-1.41%
Gross Margin
100%
Oper. Margin
-139%
Profit Margin
-140%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.03-0.0304
52W High
-
52W Low
-
RSI
50
Rel Volume
-
Avg Volume
-
Volume
3K
Perf Week
-18.92%
Perf Month
84.05%
Perf Quarter
-
Perf Half Y
-52%
-
-
-
-
Beta
0.801
-
-
Volatility
0%, 0.01%
Prev Close
0%
Price
0.03
Change
0%
SABSW Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.08 | 21.75 | 22.27 | 5.49 | 0.41 | |
| Net income per share | -0.22 | 7.92 | -6.38 | -4.31 | -7.64 | |
| Operating cash flow per share | -0.21 | 3.94 | 1.37 | 0.86 | -4.55 | |
| Free cash flow per share | -0.23 | -1.07 | -2.63 | -1.65 | -4.59 | |
| Cash per share | 0.15 | 4.97 | 12.15 | 3.46 | 10.24 | |
| Book value per share | -0.05 | 15.36 | 14.1 | 7.14 | 10.38 | |
| Tangible book value per share | -0.05 | 15.36 | 14.1 | 7.14 | 10.38 | |
| Share holders equity per share | -0.05 | 15.36 | 14.1 | 7.14 | 10.38 | |
| Interest debt per share | 0.19 | 3.39 | 2.57 | 1.43 | 1.01 | |
| Market cap | 4.41B | 257.72M | 213.52M | 25.68M | 37.99M | |
| Enterprise value | 4.41B | 253.24M | 187.06M | 16.56M | -12.67M | |
| P/E ratio | -468.57 | 12.81 | -12.24 | -1.37 | -0.9 | |
| Price to sales ratio | 1.28K | 4.67 | 3.51 | 1.07 | 16.97 | |
| POCF ratio | -478.89 | 25.76 | 56.81 | 6.83 | -1.51 | |
| PFCF ratio | -449.21 | -94.51 | -29.72 | -3.57 | -1.5 | |
| P/B Ratio | -1.91K | 6.61 | 5.54 | 0.83 | 0.66 | |
| PTB ratio | -1.91K | 6.61 | 5.54 | 0.83 | 0.66 | |
| EV to sales | 1.28K | 4.58 | 3.07 | 0.69 | -5.66 | |
| Enterprise value over EBITDA | -536.04 | 11.98 | -15.97 | -0.61 | 0.37 | |
| EV to operating cash flow | -479.03 | 25.31 | 49.77 | 4.41 | 0.5 | |
| EV to free cash flow | -449.34 | -92.87 | -26.03 | -2.3 | 0.5 | |
| Earnings yield | 0 | 0.08 | -0.08 | -0.73 | -1.11 | |
| Free cash flow yield | 0 | -0.01 | -0.03 | -0.28 | -0.67 | |
| Debt to equity | -3.31 | 0.21 | 0.17 | 0.19 | 0.1 | |
| Debt to assets | 0.42 | 0.14 | 0.08 | 0.12 | 0.07 | |
| Net debt to EBITDA | -0.16 | -0.21 | 2.26 | 0.34 | 1.48 | |
| Current ratio | 2.01 | 3.11 | 1.96 | 1.47 | 5.45 | |
| Interest coverage | -20.24 | 43.82 | -45.48 | -95.89 | 120.77 | |
| Income quality | 1.03 | 0.5 | -0.22 | -0.22 | 0.6 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 1.19 | 0.12 | 0.28 | 0.69 | 10.63 | |
| Research and developement to revenue | 2.33 | 0.51 | 0.94 | 1.52 | 7.38 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.07 | -1.27 | -2.91 | -2.91 | 0.01 | |
| Capex to revenue | -0.18 | -0.23 | -0.18 | -0.46 | -0.09 | |
| Capex to depreciation | -1.88 | -23.23 | -6.62 | -6.62 | -0.05 | |
| Stock based compensation to revenue | 0.11 | 0.02 | 0.04 | 0.1 | 1.08 | |
| Graham number | 0.51 | 52.33 | 44.99 | 26.29 | 42.24 | |
| ROIC | -0.79 | 0.37 | -0.26 | -0.7 | -0.57 | |
| Return on tangible assets | -0.52 | 0.36 | -0.22 | -0.37 | -0.5 | |
| Graham Net | -0.27 | 4.14 | -0.59 | -0.15 | 5.42 | |
| Working capital | 4.67M | 23.39M | 23.74M | 7.1M | 48.09M | |
| Tangible asset value | -2.31M | 39.01M | 38.55M | 31.06M | 57.3M | |
| Net current asset value | -11.02M | 16.92M | 7.6M | 2.25M | 32.27M | |
| Invested capital | -3.31 | 0.21 | 0.17 | 0.19 | 0.1 | |
| Average receivables | 0 | 11.69M | 14.29M | 6.78M | 2.78M | |
| Average payables | 0 | 4.78M | 5.92M | 4.07M | 2.31M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 298.92 | 135.92 | 48.03 | 84.85 | 0 | |
| Days payables outstanding | 0 | 0 | 984.13 | 407.94 | 92.19 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 1.22 | 2.69 | 7.6 | 4.3 | 0 | |
| Payables turnover | 0 | 0 | 0.37 | 0.89 | 3.96 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 4.08 | 0.52 | -0.45 | -0.6 | -0.74 | |
| Capex per share | -0.01 | -5.01 | -4 | -2.51 | -0.04 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.43 | 0.12 | 0.02 | 0.24 | 0.05 | |
| Net income per share | -1.56 | -1.47 | -1.36 | -0.97 | -3.86 | |
| Operating cash flow per share | 5.44 | -0.32 | -0.97 | -0.99 | -2.27 | |
| Free cash flow per share | 3.68 | -0.32 | -0.98 | -1 | -2.28 | |
| Cash per share | 2.99 | 2.59 | 1.54 | 0.46 | 9.54 | |
| Book value per share | 6.16 | 4.84 | 3.91 | 2.91 | 9.67 | |
| Tangible book value per share | 6.16 | 4.84 | 3.91 | 2.91 | 9.67 | |
| Share holders equity per share | 6.16 | 4.84 | 3.91 | 2.91 | 9.67 | |
| Interest debt per share | 1.19 | 1.1 | 0.99 | 0.9 | 1.01 | |
| Market cap | 29.73M | 22.17M | 41.85M | 33.02M | 40.78M | |
| Enterprise value | 20.61M | 14.58M | 38.98M | 35.24M | -9.88M | |
| P/E ratio | -0.94 | -0.75 | -1.52 | -1.62 | -0.45 | |
| Price to sales ratio | 13.76 | 38.16 | 489.37 | 26.05 | 133.69 | |
| POCF ratio | 1.08 | -13.81 | -8.54 | -6.39 | -3.03 | |
| PFCF ratio | 1.6 | -13.63 | -8.5 | -6.28 | -3.02 | |
| P/B Ratio | 0.96 | 0.91 | 2.12 | 2.16 | 0.71 | |
| PTB ratio | 0.96 | 0.91 | 2.12 | 2.16 | 0.71 | |
| EV to sales | 9.54 | 25.08 | 455.8 | 27.81 | -32.4 | |
| Enterprise value over EBITDA | -2.64 | -2.27 | -7.02 | -8.34 | 0.55 | |
| EV to operating cash flow | 0.75 | -9.08 | -7.96 | -6.82 | 0.73 | |
| EV to free cash flow | 1.11 | -8.96 | -7.92 | -6.71 | 0.73 | |
| Earnings yield | -0.26 | -0.33 | -0.16 | -0.15 | -0.56 | |
| Free cash flow yield | 0.62 | -0.07 | -0.12 | -0.16 | -0.33 | |
| Debt to equity | 0.19 | 0.22 | 0.25 | 0.3 | 0.1 | |
| Debt to assets | 0.12 | 0.13 | 0.14 | 0.16 | 0.07 | |
| Net debt to EBITDA | 1.17 | 1.18 | 0.52 | -0.53 | 2.83 | |
| Current ratio | 1.47 | 1.1 | 0.82 | 0.34 | 5.45 | |
| Interest coverage | -89.62 | -80.12 | -85.99 | -76.37 | -242.35 | |
| Income quality | -4.37 | 0.22 | 0.71 | 1.01 | 0.59 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 1.33 | 5.93 | 33.91 | 2.03 | 48.79 | |
| Research and developement to revenue | 3.3 | 7.81 | 42.82 | 3.17 | 14.09 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | -0.32 | 0.01 | 0 | 0.02 | 0.01 | |
| Capex to revenue | -4.12 | -0.04 | -0.27 | -0.07 | -0.22 | |
| Capex to depreciation | 12.44 | -0.02 | -0.03 | -0.09 | -0.07 | |
| Stock based compensation to revenue | 0.12 | 1.04 | 7.54 | 0.5 | 1.76 | |
| Graham number | 14.72 | 12.65 | 10.96 | 7.99 | 28.96 | |
| ROIC | -0.19 | -0.22 | -0.23 | -0.23 | -0.28 | |
| Return on tangible assets | -0.15 | -0.17 | -0.19 | -0.18 | -0.27 | |
| Graham Net | -0.13 | -0.92 | -1.52 | -2.03 | 5.05 | |
| Working capital | 7.1M | 1.37M | -2M | -6.08M | 48.09M | |
| Tangible asset value | 31.06M | 24.4M | 19.72M | 15.26M | 57.3M | |
| Net current asset value | 2.25M | -3.24M | -6.72M | -9.95M | 32.27M | |
| Invested capital | 0.19 | 0.22 | 0.25 | 0.3 | 0.1 | |
| Average receivables | 9.25M | 3.16M | 563.62K | 182.06K | 0 | |
| Average payables | 4.58M | 2.56M | 1.42M | 1.24M | 1.01M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 231.43 | 118.19 | 383.2 | 0 | 0 | |
| Days payables outstanding | 358.54 | 140.87 | 141.6 | 98.92 | 90.15 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0.39 | 0.76 | 0.23 | 0 | 0 | |
| Payables turnover | 0.25 | 0.64 | 0.64 | 0.91 | 1 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.25 | -0.3 | -0.35 | -0.33 | -0.4 | |
| Capex per share | -1.77 | 0 | 0 | -0.02 | -0.01 |
SABSW Frequently Asked Questions
What is SAB Biotherapeutics, Inc. stock symbol ?
SAB Biotherapeutics, Inc. is a US stock , located in Sioux falls of Sd and trading under the symbol SABSW
What is SAB Biotherapeutics, Inc. stock quote today ?
SAB Biotherapeutics, Inc. stock price is $0.03 today.
Is SAB Biotherapeutics, Inc. stock public?
Yes, SAB Biotherapeutics, Inc. is a publicly traded company.
Company Profile
- Market Capitalization 41.42M
- Employee 57
- CEO Mr. Samuel J. Reich
- Headquarters Sioux Falls,SD,US
- IPO Date 2021-10-25
-
Website
http://www.sabbiotherapeutics.com 
SAB Biotherapeutics, Inc., a biopharmaceutical company, develops immunotherapies against infectious diseases, autoimmune diseases, and oncology. It offers SAB-142 anti-thymocyte globulin for Type 1 diabetes; SAB-176 for seasonal influenza; and SAB-301 for Middle East Respiratory Syndrome Coronavirus (MERS-COV). SAB Biotherapeutics, Inc. was incorporated in 2014 and is based in Sioux Falls, South Dakota with an additional office in Cambridge, Massachusetts.
